Ascletis Pharma Announces U.S. IND Filing Of Oral Drug Candidate ASC10 For COVID-19

Ascletis Pharma Inc. (ASCLF.PK) said that the Investigational New Drug or IND application of ASC10, an oral inhibitor drug candidate targeting RNA-dependent RNA polymerase (RdRp) for COVID-19, has been filed to the U.S. Food and Drug Administration. But, the IND filing of ASC10 in China is proceeding on track.

The company noted that ASC10-A demonstrated an excellent in vitro antiviral activity against multiple SARS-CoV-2 virus variants including Omicron in preclinical studies.

Ascletis retains full global rights for ASC10 development and commercialization.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Stocks fluctuated in morning trading on Friday before once again coming under pressure over the course of the afternoon. The major averages extended the sharp pullback seen on Thursday, ending the session at their lowest closing levels since late 2020. Consumer sentiment in the U.S. improved by less than initially estimated in the month of September, according to revised data released by the University of Michigan on Friday. The University of Michigan said the consumer sentiment index for September was downwardly revised to 58.6 from the preliminary estimate of 59.5. Chicago-area business activity unexpectedly contracted in the month of September, according to a report released by MNI Indicators on Friday. MNI Indicators said its Chicago business barometer slumped to 45.7 in September from 52.2 in August, with a reading below 50 indicating contraction. Economists had expected the business barometer to edge down to 51.8.
Follow RTT